FBLG earnings analysis
What we found in FBLG's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
FibroBiologics reported a net loss of $5.0 million for Q1 2026, comparable to a loss of $4.966 million in the prior year. Operating expenses increased to $5.068 million driven primarily by higher R&D costs due to clinical trial preparations. The company's cash and equivalents decreased to $1.5 million with an accumulated deficit of $59.2 million, indicating ongoing financial challenges.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Steady Net Loss
- Net loss for Q1 2026 was $5.0 million, virtually unchanged from $4.966 million in Q1 2025.
- Increased R&D Spend
- R&D expenses rose to $2.953 million in Q1 2026, up from $1.780 million a year prior, an increase of $1.173 million.
- Cash Position Decline
- Cash and cash equivalents decreased to $1.5 million as of March 31, 2026, down from higher levels in prior periods.
- Operational Efficiency Efforts
- Management is focusing on reducing operating expenses while maintaining R&D activities.
- Recurring Operating Losses
- The accumulated deficit reached $59.2 million as of March 31, 2026, indicating sustained financial losses.
- Compliance with Nasdaq
- Successfully maintained compliance with Nasdaq's equity rule and bid price rule, ensuring continued listing.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going Concern Warning
- There is substantial doubt regarding the company's ability to continue as a going concern due to ongoing operating losses and net cash used.
- R&D Investment Risks
- Increased expenses in R&D are necessary but pose risks of generating potential losses without guaranteed returns.
- Manufacturing Challenges
- Issues related to manufacturing processes could delay product availability and strain financial resources.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-5
What they said about what is next.
Management expects continued operating losses and is focused on raising capital to fund ongoing operations and R&D.
The filing reads worse than the one before it.
What came before.
- 10-K · February 24, 2026
- FibroBiologics is a clinical-stage biotech developing fibroblast-based therapies (CYWC628, CYMS101, CybroCellTM) and is advancing a Phase 1/2 wound-healing study planned to start in Q1 2026 and an IND for MS planned in…
- 10-Q · October 31, 2025
- FibroBiologics reported a Q3 net loss of $5,778 (net loss per share $0.13) and a nine‑month net loss of $15,402, continuing to generate no revenue. Cash and cash equivalents declined to $4,867 (from $13,985 at December…
- 10-Q · July 31, 2025
- FibroBiologics reported a Q2 2025 net loss of $4.658M (EPS -$0.12) vs net income $0.898M (EPS $0.03) in Q2 2024, driven by higher operating expenses — R&D $2.041M (Q2 2025) up from $0.975M. Cash declined to $8.845M at…
- 10-K · March 31, 2025
- FibroBiologics is a clinical-stage cell therapy company focused on fibroblast-based therapies (lead candidates: CYWC628, CYMS101, CybroCellTM) and plans a twelve-week Phase 1/2 diabetic foot ulcer trial in Australia in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing FBLG makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever